4th Glioblastoma Drug Development Summit

Accelerate the Practical Translation and Clinical Development of Meaningful Therapies for the Treatment of Glioblastoma and Other Life Threatening CNS Tumors
Glioblastoma continues to be one of the most devasting diseases, with a severe lack of options available for treatment. Between drug delivery challenges, inefficient preclinical models and post-treatment recurrence, this is one of the most difficult tumors to develop treatments for.

Returning as an in-person meeting after three years, leading experts in the field, from key decision makers in pharma and biotech to academic pioneers are excited to re-unite at the 4th Glioblastoma Drug Development Summit to celebrate successes, learn from failures and explore novel approaches in GBM drug development over the past 12 months.

With the space moving towards novel approaches such as CAR-T Therapy and RNA vaccines, using combinations to enhance existing therapies and the expansion of GBM AGILE, there is so much to unpack at the only meeting dedicated to discussing GBM research.

This focused summit will facilitate discussion and collaboration from all areas of the GBM community, evaluating new ways to address key challenges associated with drug development like overcoming the blood-brain-barrier, addressing emerging resistance and securing funding for drug development projects.

URLs:
Brochure: https://go.evvnt.com/1427445-2?pid=10018
Tickets: https://go.evvnt.com/1427445-3?pid=10018
Website: https://go.evvnt.com/1427445-0?pid=10018

Time: 08:00 - 18:00

Prices:
Conference + Workshop Day - Drug Developer: USD 3997.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + Workshop Day - Service Provider: USD 4997.00,
Conference Only - Service Provider: USD 3599.00,
Conference + Workshop Day - Academic: USD 3397.00,
Conference Only - Academic: USD 2599.00

Speakers: Henry Smilowitz, Associate Professor - Cell Biology, University of Connecticut Health Center, James Garner, Chief Executive Officer, Kazia Therapeutics Limited, Jann Sarkaria, Professor - Consultant, Radiation Oncology, Mayo Clinic, Jeffrey Skolnik, Senior Vice President - Clinical Development, Inovio Pharmaceuticals, Joanne Smith-Farrell, CEO, Be Biopharma, John de Groot, Division Chief, Neuro- Oncology, UCSF Department of Neurosurgery, Jorge Benitez, Principal Scientist, Bristol Myers Squibb, Joshua Allen, Chief Technology Officer, Chimerix Inc, Khalil Barrage, Managing Director, Public Equities, Invus Financial Advisors LLC, Kiran Reddy, Senior Managing Director, Blackstone Life Sciences Fund, Kirk Tanner, CSO and SVP Brain Tumor Investment Fund, National Brain Tumor Society, Klaus Veitinger, Venture Partner, OrbiMed Advisors, Lizabeth Leveille, Vice President and Head, Boston and European Innovation Hubs and Discovery Transactions, Merck and Co, Michael Andriole, Chief Financial Officer and Chief Business Officer, Chimerix Inc, Natalie Artzi, Assistant Professor of Medicine, Harvard Medical School, Patrick Wen, Director - Center Neuro-Oncology, Dana-Farber Cancer Institute, Paul Peter Tak, President and Chief Executive Officer, Candel Therapeutics, Peter Kolchinsky, Managing Partner, RA Capital Management, Petra Hamerlik, Principle Scientist and Translational Neuro-Oncology Chair, AstraZeneca, Robbie Huffines, Global Chairman of Investment Banking, JP Morgan Chase, Santosh Kesari, Director of Neuro-Oncology, Pacific Neuroscience Institute, Scott Rakestraw, PhD President and Managing Director, The Branta Group, Sebastian Franzinger, Senior Director - Business Development and Alliance Management, Chimerix Inc, Ted Ashburn, Chief Executive Officer, Oncorus, Tooba Cheema, Senior Director, Oncorus, Vijay Agarwal, Chief Executive Officer, Alpheus Medical